0000950170-23-059008.txt : 20231106 0000950170-23-059008.hdr.sgml : 20231106 20231106070532 ACCESSION NUMBER: 0000950170-23-059008 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231106 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231106 DATE AS OF CHANGE: 20231106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Axsome Therapeutics, Inc. CENTRAL INDEX KEY: 0001579428 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 454241907 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37635 FILM NUMBER: 231378084 BUSINESS ADDRESS: STREET 1: ONE WORLD TRADE CENTER, 22ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10007 BUSINESS PHONE: (212) 332-3241 MAIL ADDRESS: STREET 1: ONE WORLD TRADE CENTER, 22ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10007 8-K 1 axsm-20231106.htm 8-K 8-K
0001579428false00015794282023-11-062023-11-06

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 06, 2023

 

 

Axsome Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-37635

45-4241907

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

One World Trade Center, 22nd Floor

 

New York, New York

 

10007

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (212) 332-3241

 

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, Par Value $0.0001 Per Share

 

AXSM

 

Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2023, Axsome Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended September 30, 2023 and provided an update on the Company’s operations. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information included in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 hereto), shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.

Description

99.1

Press Release dated November 6, 2023.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Axsome Therapeutics, Inc.

 

 

 

 

Date:

November 6, 2023

By:

/s/ Herriot Tabuteau, M.D.

 

 

Name:

Title:

Herriot Tabuteau, M.D.
President and Chief Executive Officer

 

 EX-99.1 2 axsm-ex99_1.htm EX-99.1 EX-99.1

 

Exhibit 99.1

 

img36028404_0.jpg 

 

 

Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Total 3Q 2023 product revenue of $57.8 million, representing 244% year-over-year growth

Auvelity® 3Q 2023 net product sales of $37.7 million, representing 36% quarter-over-quarter growth

Sunosi® 3Q 2023 net product revenue of $20.1 million, representing 20% year-over-year growth

SYMPHONY Phase 3 trial of AXS-12 in narcolepsy on track for completion of enrollment in 4Q 2023; topline results expected in 1Q 2024

Phase 3 trial of solriamfetol in binge eating disorder on track for initiation in 4Q 2023

Phase 3 trial of solriamfetol in shift work disorder on track for initiation in 1Q 2024

NDA submission for AXS-14 in fibromyalgia and NDA resubmission for AXS-07 in migraine both expected in 1H 2024

Company to host conference call today at 8:00 AM Eastern

NEW YORK, Nov. 6, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the third quarter ended September 30, 2023.

“Results for the third quarter evidenced significant revenue momentum for Axsome driven by solid performance from both Auvelity and Sunosi. This positive trajectory will be further enhanced by our Auvelity field force expansion, which is expected to be fully implemented by the first quarter,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. “We also progressed our extensive and innovative neuroscience pipeline in the quarter, enabling Axsome to potentially execute on numerous important clinical and regulatory milestones over the next 12 months, including multiple potential NDA submissions, and multiple pivotal trial readouts and initiations in new indications. The advancement of our commercial portfolio and clinical programs positions us well to continue to deliver potentially life-changing new medicines to patients with serious brain disorders, and to their health care providers.”

Third Quarter 2023 Financial Highlights

•
Total product revenue for the third quarter of 2023 was $57.8 million, representing 244% year-over-year growth, and consisting of net product sales of $57.1 million and royalty revenue of $0.7 million. Total product revenue for the comparable period in 2022 was $16.8 million.
•
Auvelity® net product sales were $37.7 million for the third quarter of 2023, representing a 36% sequential increase versus the second quarter of 2023. There were no Auvelity sales in the comparable 2022 period as the product was launched in October 2022.
•
Sunosi® net product revenue was $20.1 million for the third quarter of 2023, representing 20% year-over-year growth, and consisting of $19.4 million in net product sales and $0.7 million in royalty revenue associated with Sunosi sales in out-licensed territories. Sunosi net product revenue for the comparable period in 2022 was $16.8 million.
•
Total cost of revenue was $6.5 million for the third quarter of 2023. Total cost of revenue for the comparable period in 2022 was $1.9 million.

1

 

 

•
Research and development (R&D) expenses were $28.8 million for the third quarter of 2023, compared to $14.9 million for the comparable period in 2022. The increase was primarily related to the FOCUS trial of solriamfetol in ADHD, the advancement of ongoing trials of AXS-05 and AXS-12, CMC costs associated with the anticipated NDAs for AXS-07 and AXS-14, post-marketing commitments for Auvelity and Sunosi, and higher personnel costs, including non-cash stock-based compensation.
•
Selling, general, and administrative (SG&A) expenses were $83.2 million for the third quarter of 2023, compared to $40.9 million for the comparable period in 2022. The increase was primarily related to commercial activities for Auvelity and Sunosi, and higher personnel costs related to organizational growth, including non-cash stock-based compensation.
•
Net loss for the third quarter of 2023 was $62.2 million or $(1.32) per share, compared to a net loss of $44.8 million, or $(1.07) per share, for the comparable period in 2022. The net loss in the third quarter of 2023 reflects $18.0 million in non-cash charges, comprised of $16.4 million of non-cash stock-based compensation expense, and $1.6 million of non-cash intangible asset amortization, partially offset by a $0.2 million of non-cash fair value remeasurement gain in contingent consideration.
•
Cash and cash equivalents totaled $416.6 million at September 30, 2023, compared to $200.8 million at December 31, 2022.
•
Shares of common stock outstanding were 47,317,381 at September 30, 2023.

Financial Guidance

•
Axsome believes that its current cash is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan.

Commercial Highlights

Auvelity

•
Approximately 69,000 prescriptions were reported for Auvelity in the third quarter of 2023, representing a 30% sequential increase versus the second quarter of 2023.
•
The previously announced expansion of the Auvelity sales force from 162 to 260 representatives is underway and expected to be completed in the fourth quarter of 2023. The expansion will allow for greater reach and call frequency to target health care providers, potentially significantly broadening the prescriber base for Auvelity. The increased number of representatives together with Axsome’s innovative Digital Centric Commercialization (DCC™) platform is expected to increase our reach from approximately 26,000 to approximately 44,000 physicians who write approximately 90% of new branded antidepressant prescriptions.
•
Payer coverage for Auvelity across all channels is currently at approximately 70% of all covered lives. The proportion of lives covered in the commercial and government (Medicare and Medicaid) channels are approximately 48% and approximately 100%, respectively. Active discussions with payers continue as coverage further expands and evolves.

Sunosi

•
Third quarter 2023 U.S. Sunosi total prescriptions increased by 16% versus the third quarter of 2022, and sequentially by 5% versus the second quarter of 2023.
•
Sunosi maintains broad payer coverage in the commercial channel with 95% of lives covered. Currently 83% of total lives across all channels are covered.

 

2

 

 

Development Pipeline

Axsome is advancing a portfolio of differentiated, patent-protected, CNS product candidates with five in active clinical development. Recent and anticipated progress for key pipeline programs is summarized below.

AXS-05

AXS-05 (dextromethorphan-bupropion) is Axsome’s novel, oral, investigational NMDA receptor antagonist and sigma-1 agonist being developed for Alzheimer’s disease (AD) agitation and smoking cessation. AXS-05 has been granted U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation for AD agitation.

•
Alzheimer’s Disease Agitation: The Company is conducting the ADVANCE-2 study, a Phase 3, placebo-controlled, parallel group trial to assess the efficacy and safety of AXS-05 for the treatment of AD agitation. Patients completing ADVANCE-2 may enter a long-term open label safety extension trial. Based on current enrollment trends, the Company continues to anticipate completion of ADVANCE-2 in the first half of 2024.
•
Smoking Cessation: Axsome plans to initiate a pivotal Phase 2/3 trial in this indication in 2024.

AXS-07

AXS-07 (MoSEIC™ meloxicam-rizatriptan) is Axsome’s novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine for the acute treatment of migraine.

•
Migraine: Manufacturing activities related to the planned resubmission of the New Drug Application (NDA) for AXS-07 for the acute treatment of migraine continue to progress. The Company continues to anticipate resubmission of the NDA in the first half of 2024. No additional clinical efficacy or safety trials have been requested by the FDA for a resubmission of the NDA. The Company expects the NDA resubmission to be designated as Class 2 which would be subject to a six-month review.

AXS-12

AXS-12 (reboxetine) is Axsome’s novel, oral, potent, investigational highly selective norepinephrine reuptake inhibitor for the treatment of narcolepsy. AXS-12 has been granted FDA Orphan Drug designation for the treatment of narcolepsy.

•
Narcolepsy: Axsome is conducting the SYMPHONY study, a Phase 3 randomized, multicenter, double-blind, placebo-controlled, parallel-group trial of AXS-12 in the treatment of narcolepsy. The Company is on track to complete enrollment in the SYMPHONY trial in the fourth quarter of 2023, with announcement of topline results anticipated in the first quarter of 2024.

AXS-14

AXS-14 (esreboxetine) is Axsome’s novel, oral, potent, investigational highly selective norepinephrine reuptake inhibitor for the management of fibromyalgia. Esreboxetine, the SS-enantiomer of reboxetine, is more potent and selective than racemic reboxetine.

•
Fibromyalgia: Pre-submission activities related to the planned submission of an NDA to the FDA for AXS-14 for the management of fibromyalgia are ongoing. The Company expects to submit the NDA in the first quarter of 2024. AXS-14 has previously met the primary endpoints and demonstrated positive and statistically significant results in a Phase 3 and in a Phase 2 trial for the management of fibromyalgia.

 

3

 

 

Solriamfetol

Solriamfetol is Axsome’s dopamine and norepinephrine reuptake inhibitor and TAAR1 agonist in development for the treatment of attention deficit hyperactivity disorder (ADHD), binge eating disorder (BED), and excessive sleepiness associated with shift work disorder (SWD).

•
Attention Deficit Hyperactivity Disorder: Axsome is conducting the FOCUS study, a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of ADHD in adults. The Company anticipates topline results from the FOCUS trial in the second half of 2024.
•
Binge Eating Disorder: The Company previously received positive pre-IND meeting feedback from the FDA on the development of solriamfetol for the treatment of BED and is on track to initiate a Phase 3 trial in the fourth quarter of 2023. BED is the most common eating disorder, affecting an estimated 2.8% of U.S. adults.1 Treatment options are limited with only one product currently approved for the treatment of BED.
•
Shift Work Disorder: Axsome previously received positive pre-IND meeting feedback from the FDA on the development of solriamfetol for the treatment of excessive sleepiness (ES) associated with SWD, a potentially new indication for solriamfetol and is on track to initiate a Phase 3 trial in patients with ES associated with SWD in the first quarter of 2024. An estimated one third of Americans perform shift work, of whom 10-43% are diagnosed with SWD.2-4 Treatment options are limited with only two products currently approved for the treatment of ES associated with SWD.

Corporate Update

•
In October 2023, Axsome announced the appointment of Susan Mahony, PhD, to its board of directors. Dr. Mahony most recently served on the board of directors of Horizon Therapeutics from 2019 until its acquisition by Amgen in October 2023. She was formerly Senior Vice President of Eli Lilly and Company and President of Lilly Oncology.

Anticipated Milestones

•
Regulatory and Commercial:
o
AXS-07 for migraine, NDA resubmission (1H 2024)
o
AXS-14 for fibromyalgia, NDA submission (1Q 2024)
•
Clinical Trial Results:
o
Phase 3 SYMPHONY trial of AXS-12 in narcolepsy (1Q 2024)
o
Phase 3 ADVANCE-2 trial of AXS-05 for Alzheimer’s disease agitation (1H 2024)
o
Phase 3 FOCUS trial of solriamfetol in ADHD in adults (2H 2024)
•
Clinical Trial Initiations:
o
Phase 3 trial of solriamfetol for BED (4Q 2023)
o
Phase 3 trial of solriamfetol in SWD (1Q 2024)
o
Pivotal Phase 2/3 trial of AXS-05 for smoking cessation (2024)

 

4

 

 

Conference Call Information

Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss third quarter 2023 financial results as well as to provide a corporate update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic). The live webcast can be accessed on the "Webcasts & Presentations" page of the "Investors" section of the Company’s website at axsome.com. A replay of the webcast will be available for approximately 30 days following the live event.

About Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a biopharmaceutical company developing and delivering novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. At Axsome, we are committed to developing products that meaningfully improve the lives of patients and provide new therapeutic options for physicians. For more information, please visit the Company’s website at axsome.com. The Company may occasionally disseminate material, nonpublic information on the company website.

Forward Looking Statements

Certain matters discussed in this press release are “forward-looking statements”. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the continued commercial success of our Sunosi® and Auvelity® products and the success of our efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the success, timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of our ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of our current product candidates; our ability to fund additional clinical trials to continue the advancement of our product candidates; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, our product candidates, including statements regarding the timing of any NDA submission; whether issues identified by FDA in the complete response letter may impact the potential approvability of the Company’s NDA for AXS-07 for the acute treatment of migraine in adults with or without aura, pursuant to our special protocol assessment for the MOMENTUM clinical trial; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the continued commercialization of Sunosi and Auvelity and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19; and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.

 

 

5

 

 

Axsome Therapeutics, Inc.

Selected Consolidated Financial Data

 

Axsome Therapeutics, Inc.

Consolidated Balance Sheets

(In thousands, except for share and par value amounts)

 

 

 

 

September 30,

 

 

December 31,

 

 

 

2023

 

 

2022

 

 

 

(Unaudited)

 

 

 

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

416,564

 

 

$

200,842

 

Accounts receivables, net

 

 

78,415

 

 

 

37,699

 

Inventories, net

 

 

9,985

 

 

 

4,320

 

Prepaid and other current assets

 

 

6,799

 

 

 

2,781

 

Total current assets

 

 

511,763

 

 

 

245,642

 

Equipment, net

 

 

971

 

 

 

722

 

Right-of-use asset - operating lease

 

 

7,068

 

 

 

420

 

Goodwill

 

 

12,042

 

 

 

10,310

 

Intangible asset, net

 

 

54,893

 

 

 

59,661

 

Non-current inventory and other assets

 

 

14,120

 

 

 

14,721

 

Total assets

 

$

600,857

 

 

$

331,476

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

29,098

 

 

$

38,605

 

Accrued expenses and other current liabilities

 

 

78,454

 

 

 

51,631

 

Operating lease liability, current portion

 

 

438

 

 

 

425

 

Contingent consideration, current

 

 

6,672

 

 

 

5,900

 

Total current liabilities

 

 

114,662

 

 

 

96,561

 

Contingent consideration, non-current

 

 

31,550

 

 

 

31,100

 

Loan payable, long-term

 

 

177,446

 

 

 

94,259

 

Operating lease liability, long-term

 

 

7,691

 

 

 

—

 

Total liabilities

 

 

331,349

 

 

 

221,920

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock, $0.0001 par value per share (10,000,000 shares authorized, none issued and outstanding at September 30, 2023 and December 31, 2022, respectively)

 

 

—

 

 

 

—

 

Common stock, $0.0001 par value per share (150,000,000 shares authorized, 47,317,381 and 43,498,617 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively)

 

 

5

 

 

 

4

 

Additional paid-in capital

 

 

1,006,423

 

 

 

705,885

 

Accumulated deficit

 

 

(736,920

)

 

 

(596,333

)

Total stockholders’ equity

 

 

269,508

 

 

 

109,556

 

Total liabilities and stockholders’ equity

 

$

600,857

 

 

$

331,476

 

 

 

 

 

 

 

 

 

 

 

 

 

6

 

 

 

Axsome Therapeutics, Inc.

Consolidated Statements of Operations (Unaudited)

(In thousands, except share and per share amounts

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Product sales, net

 

$

57,127

 

 

$

16,846

 

 

$

131,713

 

 

$

25,666

 

License revenue

 

 

—

 

 

 

—

 

 

 

65,735

 

 

 

—

 

Royalty revenue

 

 

667

 

 

 

—

 

 

 

1,622

 

 

 

—

 

Total Revenues

 

 

57,794

 

 

 

16,846

 

 

 

199,070

 

 

 

25,666

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue (excluding amortization and depreciation)

 

 

6,532

 

 

 

1,924

 

 

 

18,687

 

 

 

2,907

 

Research and development

 

 

28,767

 

 

 

14,877

 

 

 

67,141

 

 

 

43,254

 

Selling, general and administrative

 

 

83,188

 

 

 

40,892

 

 

 

236,314

 

 

 

97,756

 

Loss (Gain) in fair value of contingent consideration

 

 

(180

)

 

 

(42

)

 

 

5,711

 

 

 

(902

)

Intangible asset amortization

 

 

1,607

 

 

 

1,607

 

 

 

4,768

 

 

 

2,532

 

Total operating expenses

 

 

119,914

 

 

 

59,258

 

 

 

332,621

 

 

 

145,547

 

Loss from operations

 

 

(62,120

)

 

 

(42,412

)

 

 

(133,551

)

 

 

(119,881

)

Interest expense, net

 

 

(757

)

 

 

(2,411

)

 

 

(5,751

)

 

 

(6,012

)

Loss before income taxes

 

 

(62,877

)

 

 

(44,823

)

 

 

(139,302

)

 

 

(125,893

)

Income tax benefit (expense)

 

 

678

 

 

 

—

 

 

 

(1,285

)

 

 

—

 

Net loss

 

$

(62,199

)

 

$

(44,823

)

 

$

(140,587

)

 

$

(125,893

)

Net loss per common share, basic and diluted

 

$

(1.32

)

 

$

(1.07

)

 

$

(3.14

)

 

$

(3.17

)

Weighted average common shares outstanding, basic and diluted

 

 

47,117,196

 

 

 

41,704,362

 

 

 

44,783,380

 

 

 

39,715,261

 

 

 

Axsome Contacts:

Investors:

Mark Jacobson

Chief Operating Officer

Axsome Therapeutics, Inc.

One World Trade Center, 22nd Floor

New York, NY 10007

Tel: 212-332-3243

Email: mjacobson@axsome.com

www.axsome.com

 

Media:

Darren Opland

Director, Corporate Communications

Axsome Therapeutics, Inc.

One World Trade Center, 22nd Floor

New York, NY 10007

Tel: 929-837-1065

Email: dopland@axsome.com

www.axsome.com

 

 

7

 

 

References:

1.
J. I. Hudson, E. Hiripi, H. G. Pope, and R. C. Kessler, “The Prevalence and Correlates of Eating Disorders in the National Comorbidity Survey Replication,” Biol. Psychiatry, vol. 61, no. 3, pp. 348–358, Feb. 2007, doi: 10.1016/j.biopsych.2006.03.040.
2.
Alterman, T., Luckhaupt, S. E., Dahlhamer, J. M., Ward, B. W. & Calvert, G. M. Prevalence rates of work organization characteristics among workers in the U.S.: data from the 2010 National Health Interview Survey. Am. J. Ind. Med. 56, 647–659 (2013).
3.
Drake, C. L., Roehrs, T., Richardson, G., Walsh, J. K. & Roth, T. Shift work sleep disorder: prevalence and consequences beyond that of symptomatic day workers. Sleep 27, 1453–1462 (2004).
4.
Wickwire, E. M., Geiger-Brown, J., Scharf, S. M. & Drake, C. L. Shift Work and Shift Work Sleep Disorder: Clinical and Organizational Perspectives. Chest 151, 1156–1172 (2017).

 

8

 

 GRAPHIC 3 img36028404_0.jpg GRAPHIC begin 644 img36028404_0.jpg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end EX-101.SCH 4 axsm-20231106.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 5 axsm-20231106_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 6 axsm-20231106_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Securities Act File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document And Entity Information
Nov. 06, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 06, 2023
Entity Registrant Name Axsome Therapeutics, Inc.
Entity Central Index Key 0001579428
Entity Emerging Growth Company false
Securities Act File Number 001-37635
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 45-4241907
Entity Address, Address Line One One World Trade Center, 22nd Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10007
City Area Code (212)
Local Phone Number 332-3241
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, Par Value $0.0001 Per Share
Trading Symbol AXSM
Security Exchange Name NASDAQ
XML 8 axsm-20231106_htm.xml IDEA: XBRL DOCUMENT 0001579428 2023-11-06 2023-11-06 0001579428 false 8-K 2023-11-06 Axsome Therapeutics, Inc. DE 001-37635 45-4241907 One World Trade Center, 22nd Floor New York NY 10007 (212) 332-3241 false false false false Common Stock, Par Value $0.0001 Per Share AXSM NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://axsome.com/20231106/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports axsm-20231106.htm axsm-20231106.xsd axsm-20231106_lab.xml axsm-20231106_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "axsm-20231106.htm": { "nsprefix": "axsm", "nsuri": "http://axsome.com/20231106", "dts": { "inline": { "local": [ "axsm-20231106.htm" ] }, "schema": { "local": [ "axsm-20231106.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "axsm-20231106_lab.xml" ] }, "presentationLink": { "local": [ "axsm-20231106_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://axsome.com/20231106/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_1f410f02-b894-4a09-a248-b186a1332821", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "axsm-20231106.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1f410f02-b894-4a09-a248-b186a1332821", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "axsm-20231106.htm", "first": true, "unique": true } } }, "tag": { "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://axsome.com/20231106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://axsome.com/20231106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://axsome.com/20231106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://axsome.com/20231106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://axsome.com/20231106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://axsome.com/20231106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://axsome.com/20231106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://axsome.com/20231106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://axsome.com/20231106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://axsome.com/20231106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://axsome.com/20231106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://axsome.com/20231106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://axsome.com/20231106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://axsome.com/20231106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://axsome.com/20231106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://axsome.com/20231106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://axsome.com/20231106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://axsome.com/20231106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://axsome.com/20231106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://axsome.com/20231106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://axsome.com/20231106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://axsome.com/20231106/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0000950170-23-059008-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-059008-xbrl.zip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end